RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Immunodiagnostic Systems Holdings - Stock

Immunodiagnostic Systems Holdings Stocks 2024

Immunodiagnostic Systems Holdings Stocks

28.81 M

Ticker

IDH.L

ISIN

GB00B01YZ052

WKN

A0D9MS

In 2024, Immunodiagnostic Systems Holdings had 28.81 M outstanding stocks, a -0.84% change from the 29.05 M stocks in the previous year.

The Immunodiagnostic Systems Holdings Stocks history

YEARNUMBER OF STOCKS (undefined GBP)
202028.81
201929.05
201829.44
201729.42
201629.33
201529.43
201429.29
201328.65
201229.3
201129.11
201027.92
200925.96
200821.03
200714.59
200613.34
20058.13
20046.98

Immunodiagnostic Systems Holdings shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Immunodiagnostic Systems Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Immunodiagnostic Systems Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Immunodiagnostic Systems Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Immunodiagnostic Systems Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Immunodiagnostic Systems Holdings Aktienanalyse

What does Immunodiagnostic Systems Holdings do?

IDS, Immunodiagnostic Systems Holdings PLC, is an English-American diagnostic company that specializes in the development, manufacture, and marketing of diagnostic tests for various applications. The company was founded in 1977 in Boldon, England and is headquartered in Tyne and Wear. IDS started with a focus on researching enzyme immunoassays (EIA) and has expanded its offerings to include radioimmunoassays and chemiluminescent tests. IDS operates in sectors such as endocrinology, clinical chemistry, hematology, and oncology, and is known as a leading provider of diagnostic test kits in many countries. The company offers over 400 tests, including reagents, calibrators, controls, and devices for more than 200 different parameters. IDS sells its products through an international network of branches, distributors, and authorized dealers in Asia, Europe, North America, South America, and the Middle East. The company has also established subsidiaries in the US and China to expand its offerings and drive growth in these regions. IDS's business model is focused on meeting customer needs for reliable, accurate, and fast diagnostic solutions. The company adheres to the highest quality standards and is committed to the continuous development and improvement of its products to enhance patient care and laboratory work worldwide. IDS has made a name for itself in the diagnostic industry in recent years and is a pioneer in developing tests for emerging applications such as autoimmune diseases and food intolerances. The company invests heavily in research and development and collaborates closely with academic partners and research institutions to identify and develop innovative diagnostic solutions. In summary, IDS is a leading diagnostic company operating in various applications and offering a wide range of diagnostic test solutions. The company has experienced strong growth in recent years and is committed to expanding its product range and offerings to meet the needs of patients and laboratories worldwide. Immunodiagnostic Systems Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Immunodiagnostic Systems Holdings's Shares Outstanding

Immunodiagnostic Systems Holdings's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Immunodiagnostic Systems Holdings’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Immunodiagnostic Systems Holdings’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Immunodiagnostic Systems Holdings’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Immunodiagnostic Systems Holdings Stock

How many stocks are there of Immunodiagnostic Systems Holdings?

The current number of stocks of Immunodiagnostic Systems Holdings is 28.81 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Immunodiagnostic Systems Holdings are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Immunodiagnostic Systems Holdings evolved in recent years?

The number of shares of Immunodiagnostic Systems Holdings has increased by -0.84% gesunken compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Immunodiagnostic Systems Holdings as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Immunodiagnostic Systems Holdings?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Immunodiagnostic Systems Holdings pay?

Over the past 12 months, Immunodiagnostic Systems Holdings paid a dividend of 0.02 GBP . This corresponds to a dividend yield of about 50.26 %. For the coming 12 months, Immunodiagnostic Systems Holdings is expected to pay a dividend of 0.02 GBP.

What is the dividend yield of Immunodiagnostic Systems Holdings?

The current dividend yield of Immunodiagnostic Systems Holdings is 50.26 %.

When does Immunodiagnostic Systems Holdings pay dividends?

Immunodiagnostic Systems Holdings pays a quarterly dividend. This is distributed in the months of August, August, August, August.

How secure is the dividend of Immunodiagnostic Systems Holdings?

Immunodiagnostic Systems Holdings paid dividends every year for the past 15 years.

What is the dividend of Immunodiagnostic Systems Holdings?

For the upcoming 12 months, dividends amounting to 0.02 GBP are expected. This corresponds to a dividend yield of 50.26 %.

In which sector is Immunodiagnostic Systems Holdings located?

Immunodiagnostic Systems Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immunodiagnostic Systems Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immunodiagnostic Systems Holdings from 8/14/2020 amounting to 0.019 GBP, you needed to have the stock in your portfolio before the ex-date on 7/16/2020.

When did Immunodiagnostic Systems Holdings pay the last dividend?

The last dividend was paid out on 8/14/2020.

What was the dividend of Immunodiagnostic Systems Holdings in the year 2023?

In the year 2023, Immunodiagnostic Systems Holdings distributed 0.007 GBP as dividends.

In which currency does Immunodiagnostic Systems Holdings pay out the dividend?

The dividends of Immunodiagnostic Systems Holdings are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Immunodiagnostic Systems Holdings

Our stock analysis for Immunodiagnostic Systems Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunodiagnostic Systems Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.